AdaptHealth Corp. (AHCO) Stock Competitors & Peer Comparison

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AHCO is priced at $10.13, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AHCO's ROE is -0.05%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, AHCO is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check BSX-PA's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ISRG has a market cap of 150.4B. Regarding current trading prices, AHCO is priced at $10.13, while ISRG trades at $424.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ISRG's P/E ratio is 51.66. In terms of profitability, AHCO's ROE is -0.05%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, AHCO is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check ISRG's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ABT has a market cap of 149.1B. Regarding current trading prices, AHCO is priced at $10.13, while ABT trades at $85.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ABT's P/E ratio is 23.97. In terms of profitability, AHCO's ROE is -0.05%, compared to ABT's ROE of +0.12%. Regarding short-term risk, AHCO is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check ABT's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SYK has a market cap of 117B. Regarding current trading prices, AHCO is priced at $10.13, while SYK trades at $305.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SYK's P/E ratio is 35.33. In terms of profitability, AHCO's ROE is -0.05%, compared to SYK's ROE of +0.15%. Regarding short-term risk, AHCO is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check SYK's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, MDT has a market cap of 94.8B. Regarding current trading prices, AHCO is priced at $10.13, while MDT trades at $73.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas MDT's P/E ratio is 20.62. In terms of profitability, AHCO's ROE is -0.05%, compared to MDT's ROE of +0.10%. Regarding short-term risk, AHCO is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check MDT's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BSX has a market cap of 71.8B. Regarding current trading prices, AHCO is priced at $10.13, while BSX trades at $48.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BSX's P/E ratio is 20.22. In terms of profitability, AHCO's ROE is -0.05%, compared to BSX's ROE of +0.15%. Regarding short-term risk, AHCO is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check BSX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BRKRP has a market cap of 66.3B. Regarding current trading prices, AHCO is priced at $10.13, while BRKRP trades at $436.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BRKRP's P/E ratio is N/A. In terms of profitability, AHCO's ROE is -0.05%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, AHCO is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check BRKRP's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, EW has a market cap of 49.8B. Regarding current trading prices, AHCO is priced at $10.13, while EW trades at $86.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas EW's P/E ratio is 46.74. In terms of profitability, AHCO's ROE is -0.05%, compared to EW's ROE of +0.11%. Regarding short-term risk, AHCO is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check EW's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, DXCM has a market cap of 28.5B. Regarding current trading prices, AHCO is priced at $10.13, while DXCM trades at $73.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas DXCM's P/E ratio is 31.65. In terms of profitability, AHCO's ROE is -0.05%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, AHCO is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check DXCM's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, RMD has a market cap of 27.7B. Regarding current trading prices, AHCO is priced at $10.13, while RMD trades at $190.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas RMD's P/E ratio is 18.38. In terms of profitability, AHCO's ROE is -0.05%, compared to RMD's ROE of +0.24%. Regarding short-term risk, AHCO is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check RMD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, PHG has a market cap of 25.1B. Regarding current trading prices, AHCO is priced at $10.13, while PHG trades at $26.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas PHG's P/E ratio is 22.74. In terms of profitability, AHCO's ROE is -0.05%, compared to PHG's ROE of +0.09%. Regarding short-term risk, AHCO is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check PHG's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, STE has a market cap of 20.9B. Regarding current trading prices, AHCO is priced at $10.13, while STE trades at $212.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas STE's P/E ratio is 26.82. In terms of profitability, AHCO's ROE is -0.05%, compared to STE's ROE of +0.11%. Regarding short-term risk, AHCO is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check STE's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AHCO is priced at $10.13, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AHCO's ROE is -0.05%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AHCO is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check ABMD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ZBH has a market cap of 15.9B. Regarding current trading prices, AHCO is priced at $10.13, while ZBH trades at $82.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ZBH's P/E ratio is 21.33. In terms of profitability, AHCO's ROE is -0.05%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, AHCO is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check ZBH's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, AHCO is priced at $10.13, while SNN trades at $29.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SNN's P/E ratio is 20.76. In terms of profitability, AHCO's ROE is -0.05%, compared to SNN's ROE of +0.12%. Regarding short-term risk, AHCO is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check SNN's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AHCO is priced at $10.13, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AHCO's ROE is -0.05%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, AHCO is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check SWAV's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ALGN has a market cap of 12.5B. Regarding current trading prices, AHCO is priced at $10.13, while ALGN trades at $174.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ALGN's P/E ratio is 27.64. In terms of profitability, AHCO's ROE is -0.05%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, AHCO is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check ALGN's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, AHCO is priced at $10.13, while PEN trades at $318.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas PEN's P/E ratio is 73.50. In terms of profitability, AHCO's ROE is -0.05%, compared to PEN's ROE of +0.12%. Regarding short-term risk, AHCO is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check PEN's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, GMED has a market cap of 11B. Regarding current trading prices, AHCO is priced at $10.13, while GMED trades at $81.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas GMED's P/E ratio is 19.14. In terms of profitability, AHCO's ROE is -0.05%, compared to GMED's ROE of +0.13%. Regarding short-term risk, AHCO is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check GMED's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, PODD has a market cap of 10B. Regarding current trading prices, AHCO is priced at $10.13, while PODD trades at $144.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas PODD's P/E ratio is 33.86. In terms of profitability, AHCO's ROE is -0.05%, compared to PODD's ROE of +0.21%. Regarding short-term risk, AHCO is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check PODD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, MASI has a market cap of 9.3B. Regarding current trading prices, AHCO is priced at $10.13, while MASI trades at $178.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas MASI's P/E ratio is 44.17. In terms of profitability, AHCO's ROE is -0.05%, compared to MASI's ROE of +0.09%. Regarding short-term risk, AHCO is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check MASI's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BRKR has a market cap of 9B. Regarding current trading prices, AHCO is priced at $10.13, while BRKR trades at $58.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BRKR's P/E ratio is -245.42. In terms of profitability, AHCO's ROE is -0.05%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, AHCO is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check BRKR's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BIO-B has a market cap of 8.5B. Regarding current trading prices, AHCO is priced at $10.13, while BIO-B trades at $313.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BIO-B's P/E ratio is 52.10. In terms of profitability, AHCO's ROE is -0.05%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, AHCO is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check BIO-B's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BIO has a market cap of 8.4B. Regarding current trading prices, AHCO is priced at $10.13, while BIO trades at $312.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BIO's P/E ratio is 51.99. In terms of profitability, AHCO's ROE is -0.05%, compared to BIO's ROE of +0.02%. Regarding short-term risk, AHCO is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check BIO's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, GKOS has a market cap of 6.1B. Regarding current trading prices, AHCO is priced at $10.13, while GKOS trades at $103.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas GKOS's P/E ratio is -31.35. In terms of profitability, AHCO's ROE is -0.05%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, AHCO is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check GKOS's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AHCO is priced at $10.13, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas NARI's P/E ratio is -59.24. In terms of profitability, AHCO's ROE is -0.05%, compared to NARI's ROE of -0.00%. Regarding short-term risk, AHCO is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check NARI's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, LIVN has a market cap of 4.1B. Regarding current trading prices, AHCO is priced at $10.13, while LIVN trades at $73.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas LIVN's P/E ratio is 37.65. In terms of profitability, AHCO's ROE is -0.05%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, AHCO is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check LIVN's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, AHCO is priced at $10.13, while IRTC trades at $113.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas IRTC's P/E ratio is -133.99. In terms of profitability, AHCO's ROE is -0.05%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, AHCO is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check IRTC's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, AHCO is priced at $10.13, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas AXNX's P/E ratio is -709.80. In terms of profitability, AHCO's ROE is -0.05%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, AHCO is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check AXNX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, AHCO is priced at $10.13, while ITGR trades at $89.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ITGR's P/E ratio is 22.19. In terms of profitability, AHCO's ROE is -0.05%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, AHCO is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check ITGR's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, AHCO is priced at $10.13, while TMDX trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas TMDX's P/E ratio is 15.38. In terms of profitability, AHCO's ROE is -0.05%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, AHCO is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check TMDX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, AHCO is priced at $10.13, while AXGN trades at $39.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas AXGN's P/E ratio is -61.69. In terms of profitability, AHCO's ROE is -0.05%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, AHCO is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check AXGN's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AHCO is priced at $10.13, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AHCO's ROE is -0.05%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AHCO is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check NUVA's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, AHCO is priced at $10.13, while ESTA trades at $70.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ESTA's P/E ratio is -48.09. In terms of profitability, AHCO's ROE is -0.05%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, AHCO is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check ESTA's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, AHCO is priced at $10.13, while UFPT trades at $220.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas UFPT's P/E ratio is 25.07. In terms of profitability, AHCO's ROE is -0.05%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, AHCO is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check UFPT's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, AHCO is priced at $10.13, while PRCT trades at $26.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas PRCT's P/E ratio is -14.39. In terms of profitability, AHCO's ROE is -0.05%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, AHCO is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check PRCT's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AHCO is priced at $10.13, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AHCO's ROE is -0.05%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AHCO is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check HSKA's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, AHCO is priced at $10.13, while ENOV trades at $22.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ENOV's P/E ratio is -1.14. In terms of profitability, AHCO's ROE is -0.05%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, AHCO is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check ENOV's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, AHCO is priced at $10.13, while IART trades at $16.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas IART's P/E ratio is -2.48. In terms of profitability, AHCO's ROE is -0.05%, compared to IART's ROE of -0.48%. Regarding short-term risk, AHCO is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check IART's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, AHCO is priced at $10.13, while INSP trades at $41.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas INSP's P/E ratio is 9.40. In terms of profitability, AHCO's ROE is -0.05%, compared to INSP's ROE of +0.18%. Regarding short-term risk, AHCO is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check INSP's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, AHCO is priced at $10.13, while ATEC trades at $7.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ATEC's P/E ratio is -9.34. In terms of profitability, AHCO's ROE is -0.05%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, AHCO is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check ATEC's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, AHCO is priced at $10.13, while BFLY trades at $4.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BFLY's P/E ratio is -15.03. In terms of profitability, AHCO's ROE is -0.05%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, AHCO is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check BFLY's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, AHCO is priced at $10.13, while TNDM trades at $17.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas TNDM's P/E ratio is -12.55. In terms of profitability, AHCO's ROE is -0.05%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, AHCO is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check TNDM's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, AHCO is priced at $10.13, while AVNS trades at $24.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas AVNS's P/E ratio is -15.50. In terms of profitability, AHCO's ROE is -0.05%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, AHCO is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check AVNS's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, AHCO is priced at $10.13, while IRMD trades at $90.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas IRMD's P/E ratio is 49.54. In terms of profitability, AHCO's ROE is -0.05%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, AHCO is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check IRMD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AHCO is priced at $10.13, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SILK's P/E ratio is -18.96. In terms of profitability, AHCO's ROE is -0.05%, compared to SILK's ROE of -0.35%. Regarding short-term risk, AHCO is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check SILK's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AHCO is priced at $10.13, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas FNA's P/E ratio is -19.83. In terms of profitability, AHCO's ROE is -0.05%, compared to FNA's ROE of -0.35%. Regarding short-term risk, AHCO is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check FNA's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, AHCO is priced at $10.13, while AORT trades at $22.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas AORT's P/E ratio is 88.74. In terms of profitability, AHCO's ROE is -0.05%, compared to AORT's ROE of +0.03%. Regarding short-term risk, AHCO is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check AORT's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, AHCO is priced at $10.13, while CNMD trades at $35.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CNMD's P/E ratio is 20.18. In terms of profitability, AHCO's ROE is -0.05%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, AHCO is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check CNMD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, INMD has a market cap of 882.6M. Regarding current trading prices, AHCO is priced at $10.13, while INMD trades at $13.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas INMD's P/E ratio is 10.32. In terms of profitability, AHCO's ROE is -0.05%, compared to INMD's ROE of +0.13%. Regarding short-term risk, AHCO is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check INMD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AHCO is priced at $10.13, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CSII's P/E ratio is -20.83. In terms of profitability, AHCO's ROE is -0.05%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AHCO is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check CSII's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SSII has a market cap of 788.5M. Regarding current trading prices, AHCO is priced at $10.13, while SSII trades at $3.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SSII's P/E ratio is -78.80. In terms of profitability, AHCO's ROE is -0.05%, compared to SSII's ROE of -0.23%. Regarding short-term risk, AHCO is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check SSII's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, LMRI has a market cap of 745.6M. Regarding current trading prices, AHCO is priced at $10.13, while LMRI trades at $7.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas LMRI's P/E ratio is -20.97. In terms of profitability, AHCO's ROE is -0.05%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, AHCO is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check LMRI's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, AHCO is priced at $10.13, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CRY's P/E ratio is 425.71. In terms of profitability, AHCO's ROE is -0.05%, compared to CRY's ROE of +0.03%. Regarding short-term risk, AHCO is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check CRY's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CBLL has a market cap of 699.3M. Regarding current trading prices, AHCO is priced at $10.13, while CBLL trades at $18.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CBLL's P/E ratio is -11.38. In terms of profitability, AHCO's ROE is -0.05%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, AHCO is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check CBLL's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SIBN has a market cap of 625.3M. Regarding current trading prices, AHCO is priced at $10.13, while SIBN trades at $14.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SIBN's P/E ratio is -36.15. In terms of profitability, AHCO's ROE is -0.05%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, AHCO is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check SIBN's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BWAY has a market cap of 622.9M. Regarding current trading prices, AHCO is priced at $10.13, while BWAY trades at $15.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BWAY's P/E ratio is 72.18. In terms of profitability, AHCO's ROE is -0.05%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, AHCO is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check BWAY's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, AHCO is priced at $10.13, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SRDX's P/E ratio is -34.66. In terms of profitability, AHCO's ROE is -0.05%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, AHCO is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check SRDX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CERS has a market cap of 609.1M. Regarding current trading prices, AHCO is priced at $10.13, while CERS trades at $3.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CERS's P/E ratio is -60.80. In terms of profitability, AHCO's ROE is -0.05%, compared to CERS's ROE of -0.15%. Regarding short-term risk, AHCO is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check CERS's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AHCO is priced at $10.13, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas APEN's P/E ratio is -9.43. In terms of profitability, AHCO's ROE is -0.05%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AHCO is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check APEN's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BVS has a market cap of 576.5M. Regarding current trading prices, AHCO is priced at $10.13, while BVS trades at $8.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BVS's P/E ratio is 20.76. In terms of profitability, AHCO's ROE is -0.05%, compared to BVS's ROE of +0.16%. Regarding short-term risk, AHCO is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check BVS's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, NPCE has a market cap of 563.9M. Regarding current trading prices, AHCO is priced at $10.13, while NPCE trades at $16.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas NPCE's P/E ratio is -25.06. In terms of profitability, AHCO's ROE is -0.05%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, AHCO is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check NPCE's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, TCMD has a market cap of 555.1M. Regarding current trading prices, AHCO is priced at $10.13, while TCMD trades at $24.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas TCMD's P/E ratio is 28.29. In terms of profitability, AHCO's ROE is -0.05%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, AHCO is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check TCMD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CTKB has a market cap of 541.1M. Regarding current trading prices, AHCO is priced at $10.13, while CTKB trades at $4.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CTKB's P/E ratio is -7.22. In terms of profitability, AHCO's ROE is -0.05%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, AHCO is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check CTKB's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, AHCO is priced at $10.13, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, AHCO's ROE is -0.05%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, AHCO is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check ZIMV's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, PACB has a market cap of 462.8M. Regarding current trading prices, AHCO is priced at $10.13, while PACB trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas PACB's P/E ratio is -3.63. In terms of profitability, AHCO's ROE is -0.05%, compared to PACB's ROE of -4.88%. Regarding short-term risk, AHCO is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check PACB's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, LAB has a market cap of 448.9M. Regarding current trading prices, AHCO is priced at $10.13, while LAB trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas LAB's P/E ratio is -8.85. In terms of profitability, AHCO's ROE is -0.05%, compared to LAB's ROE of -0.21%. Regarding short-term risk, AHCO is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check LAB's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, KIDS has a market cap of 441M. Regarding current trading prices, AHCO is priced at $10.13, while KIDS trades at $17.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas KIDS's P/E ratio is -10.22. In terms of profitability, AHCO's ROE is -0.05%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, AHCO is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check KIDS's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, VREX has a market cap of 430.7M. Regarding current trading prices, AHCO is priced at $10.13, while VREX trades at $10.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas VREX's P/E ratio is -5.11. In terms of profitability, AHCO's ROE is -0.05%, compared to VREX's ROE of -0.18%. Regarding short-term risk, AHCO is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check VREX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CLPT has a market cap of 380M. Regarding current trading prices, AHCO is priced at $10.13, while CLPT trades at $12.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CLPT's P/E ratio is -12.67. In terms of profitability, AHCO's ROE is -0.05%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, AHCO is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check CLPT's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, VMD has a market cap of 377.2M. Regarding current trading prices, AHCO is priced at $10.13, while VMD trades at $9.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas VMD's P/E ratio is 25.89. In terms of profitability, AHCO's ROE is -0.05%, compared to VMD's ROE of +0.11%. Regarding short-term risk, AHCO is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check VMD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, OFIX has a market cap of 374.7M. Regarding current trading prices, AHCO is priced at $10.13, while OFIX trades at $9.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas OFIX's P/E ratio is -6.18. In terms of profitability, AHCO's ROE is -0.05%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, AHCO is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check OFIX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, DCTH has a market cap of 372.1M. Regarding current trading prices, AHCO is priced at $10.13, while DCTH trades at $10.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas DCTH's P/E ratio is 1078.00. In terms of profitability, AHCO's ROE is -0.05%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, AHCO is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check DCTH's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, MASS has a market cap of 318M. Regarding current trading prices, AHCO is priced at $10.13, while MASS trades at $8.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas MASS's P/E ratio is -8.67. In terms of profitability, AHCO's ROE is -0.05%, compared to MASS's ROE of -0.26%. Regarding short-term risk, AHCO is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check MASS's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, AVR has a market cap of 317.1M. Regarding current trading prices, AHCO is priced at $10.13, while AVR trades at $8.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas AVR's P/E ratio is -3.88. In terms of profitability, AHCO's ROE is -0.05%, compared to AVR's ROE of -1.24%. Regarding short-term risk, AHCO is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check AVR's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ELMD has a market cap of 313.6M. Regarding current trading prices, AHCO is priced at $10.13, while ELMD trades at $37.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ELMD's P/E ratio is 32.37. In terms of profitability, AHCO's ROE is -0.05%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, AHCO is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check ELMD's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, AHCO is priced at $10.13, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SMLR's P/E ratio is 3.92. In terms of profitability, AHCO's ROE is -0.05%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, AHCO is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check SMLR's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CATX has a market cap of 304.8M. Regarding current trading prices, AHCO is priced at $10.13, while CATX trades at $3.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CATX's P/E ratio is -2.80. In terms of profitability, AHCO's ROE is -0.05%, compared to CATX's ROE of -0.42%. Regarding short-term risk, AHCO is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check CATX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SENS has a market cap of 283.6M. Regarding current trading prices, AHCO is priced at $10.13, while SENS trades at $6.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SENS's P/E ratio is -3.45. In terms of profitability, AHCO's ROE is -0.05%, compared to SENS's ROE of -1.30%. Regarding short-term risk, AHCO is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check SENS's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SGHT has a market cap of 264.4M. Regarding current trading prices, AHCO is priced at $10.13, while SGHT trades at $4.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SGHT's P/E ratio is -6.94. In terms of profitability, AHCO's ROE is -0.05%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, AHCO is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check SGHT's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, AHCO is priced at $10.13, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas MGRM's P/E ratio is -11.11. In terms of profitability, AHCO's ROE is -0.05%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, AHCO is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check MGRM's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, PMI has a market cap of 232.6M. Regarding current trading prices, AHCO is priced at $10.13, while PMI trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas PMI's P/E ratio is -0.20. In terms of profitability, AHCO's ROE is -0.05%, compared to PMI's ROE of +4.99%. Regarding short-term risk, AHCO is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check PMI's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, TMCI has a market cap of 224.5M. Regarding current trading prices, AHCO is priced at $10.13, while TMCI trades at $3.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas TMCI's P/E ratio is -3.60. In terms of profitability, AHCO's ROE is -0.05%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, AHCO is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check TMCI's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AHCO is priced at $10.13, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AHCO's ROE is -0.05%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, AHCO is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check NVRO's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, RXST has a market cap of 220.6M. Regarding current trading prices, AHCO is priced at $10.13, while RXST trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas RXST's P/E ratio is -4.72. In terms of profitability, AHCO's ROE is -0.05%, compared to RXST's ROE of -0.17%. Regarding short-term risk, AHCO is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check RXST's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, AHCO is priced at $10.13, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas EYES's P/E ratio is N/A. In terms of profitability, AHCO's ROE is -0.05%, compared to EYES's ROE of -2.64%. Regarding short-term risk, AHCO is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check EYES's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, PROF has a market cap of 206.1M. Regarding current trading prices, AHCO is priced at $10.13, while PROF trades at $6.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas PROF's P/E ratio is -5.49. In terms of profitability, AHCO's ROE is -0.05%, compared to PROF's ROE of -0.71%. Regarding short-term risk, AHCO is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check PROF's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, ANIK has a market cap of 193.3M. Regarding current trading prices, AHCO is priced at $10.13, while ANIK trades at $14.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas ANIK's P/E ratio is -18.39. In terms of profitability, AHCO's ROE is -0.05%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, AHCO is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check ANIK's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, AHCO is priced at $10.13, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas BSGM's P/E ratio is -5.81. In terms of profitability, AHCO's ROE is -0.05%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, AHCO is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check BSGM's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, AHCO is priced at $10.13, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas MDGS's P/E ratio is -0.27. In terms of profitability, AHCO's ROE is -0.05%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, AHCO is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check MDGS's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, INGN has a market cap of 175.4M. Regarding current trading prices, AHCO is priced at $10.13, while INGN trades at $6.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas INGN's P/E ratio is -7.12. In terms of profitability, AHCO's ROE is -0.05%, compared to INGN's ROE of -0.13%. Regarding short-term risk, AHCO is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check INGN's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, APYX has a market cap of 167.3M. Regarding current trading prices, AHCO is priced at $10.13, while APYX trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas APYX's P/E ratio is -18.16. In terms of profitability, AHCO's ROE is -0.05%, compared to APYX's ROE of -0.91%. Regarding short-term risk, AHCO is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check APYX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, AHCO is priced at $10.13, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas QIPT's P/E ratio is -15.87. In terms of profitability, AHCO's ROE is -0.05%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, AHCO is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check QIPT's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, EDAP has a market cap of 161.5M. Regarding current trading prices, AHCO is priced at $10.13, while EDAP trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas EDAP's P/E ratio is -5.26. In terms of profitability, AHCO's ROE is -0.05%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, AHCO is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check EDAP's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, CVRX has a market cap of 148.1M. Regarding current trading prices, AHCO is priced at $10.13, while CVRX trades at $5.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas CVRX's P/E ratio is -2.78. In terms of profitability, AHCO's ROE is -0.05%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, AHCO is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check CVRX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, QTRX has a market cap of 144.1M. Regarding current trading prices, AHCO is priced at $10.13, while QTRX trades at $3.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas QTRX's P/E ratio is -1.30. In terms of profitability, AHCO's ROE is -0.05%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, AHCO is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check QTRX's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, SNWV has a market cap of 141.6M. Regarding current trading prices, AHCO is priced at $10.13, while SNWV trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas SNWV's P/E ratio is 17.16. In terms of profitability, AHCO's ROE is -0.05%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, AHCO is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check SNWV's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, QTI has a market cap of 135.7M. Regarding current trading prices, AHCO is priced at $10.13, while QTI trades at $5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas QTI's P/E ratio is -4.76. In terms of profitability, AHCO's ROE is -0.05%, compared to QTI's ROE of -63.30%. Regarding short-term risk, AHCO is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for AHCO.Check QTI's competition here

AHCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AHCO stands at 1.4B. In comparison, NNOX has a market cap of 133.6M. Regarding current trading prices, AHCO is priced at $10.13, while NNOX trades at $1.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AHCO currently has a P/E ratio of -17.17, whereas NNOX's P/E ratio is -1.66. In terms of profitability, AHCO's ROE is -0.05%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, AHCO is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for AHCO.Check NNOX's competition here